Metabolic acidosis (MA) is a major physiological derangement associated with mortality.1 There is no specific treatment for MA, beyond treating its cause.However, the administration of buffering solutions to correct MA may be common practice in the intensive care unit (ICU).The rationale for such therapy is that, independent of its cause, MA with acidaemia impairs the performance of the cardiovascular system 2,3 and should be corrected.To reduce this perceived cardiovascular dysfunction, sodium bicarbonate is the most commonly used agent.4,5 However, until recently there have been little or no data on its effectiveness.6,7 In 2018, Jaber and colleagues 8 reported the findings of a multicentre, open-label, randomised controlled trial of the efficacy of intravenous sodium bicarbonate for critically ill patients with severe MA (BICAR-ICU trial).The trial investigators found that the administration of sodium bicarbonate reduced the use of renal replacement therapy (RRT) in the ICU, and decreased 28-day mortality in the subgroup of patients with acute kidney injury Stage 2 and 3.These findings have created renewed interest in the use of sodium bicarbonate for MA.However, it is unclear how many patients such an intervention would apply to and what the outcome of such patients in the setting of usual care might be.Moreover, for the purpose of designing and powering a trial, it is unknown whether investigators should apply more moderate criteria for MA to achieve more efficient patient selection.In particular, patients with moderate MA may also have a high mortality risk and a much greater prevalence than severe MA.This larger population would then enable the conduct of a trial with greater external validity and with recruitment that is more efficient.Accordingly, the aim of the study was to measure the incidence, prevalence, characteristics and outcomes of patients with both severe MA (using the BICAR-ICU trial criteria) and moderate MA (using new criteria) in Australian and New Zealand ICUs.